Neuroendocrine responses to levodopa in multiple system atrophy (MSA)

Movement Disorders

Volumn 14, Issue 6, 1999, Pages 981-987

  Kimber, Jeffery ^a   Watson, Laura ^b   Mathias, Christopher J ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Levodopa; Multiple system atrophy; Neuroendocrine

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LEVODOPA; PROLACTIN; SOMATOMEDIN C; THYROTROPIN;

ADENOHYPOPHYSIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HYPOTHALAMUS; MALE; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; PROLACTIN RELEASE; SHY DRAGER SYNDROME;

ADULT; AGED; ANTIPARKINSON AGENTS; BLOOD GLUCOSE; CARBIDOPA; DOPAMINE; DRUG COMBINATIONS; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN-LIKE GROWTH FACTOR I; LEVODOPA; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; REFERENCE VALUES; THYROTROPIN;

EID: 0032703201     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199911)14:6<981::AID-MDS1011>3.0.CO;2-W     Document Type: Article

References (63)

1. Boyd A, Lebovitz H, Pfeiffer J. Stimulation of human growth hormone by L-dopa. N Engl J Med 1970;283:1425.
2. Malarkey W, Jacobs L, Daughaday W. Levodopa suppression of prolactin in non puerperal galactorrhoea. N Engl J Med 1971;285: 1160-1163.
3. Malarkey W, Cyrus J, Paulson G. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy. J Clin Endocrinol Metab 1974;39:229-235.
4. Murri L, Indice L, Muratorio A, Pollerre A, Barreca T, Murialdo G. Spontaneous nocturnal plasma prolactin and GH secretion in patients with PD and Huntington's chorea. Eur Neurol 1980;19: 198-206.
5. Galea-Debono A, Jenner P, Marsden CD, Parkes J, Tarsy D, Walters J. Plasma dopa levels and GH response to L-dopa in parkinsonism. J Neurol Neurosurg Psychiatry 1977;40:162-167.
6. Eisler T, Thorner M, MacCleod R, Kaiser D, Calne D. Prolactin secretion in Parkinson's disease. Neurology 1981;31:1356-1359.
7. Martinez-Campos A, Giovanni P, Parati E, Novell A, Caraceni T, Muller EE. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44: 1116-1123.
8. Agnoli A, Ruggieri S, Falaschi P, et al. A neuropharmacological and neuroendocrine study on idiopathic and chronic pharmacological parkinsonism. Adv Biochem Psychopharmacol 1980;24:551-557.
9. Javoy-Agid F, Ruberg M, Pique L, et al. Biochemistry of the hypothalamus in Parkinson's disease. Neurology 1984;34:672-676.
10. Langston J, Forno L. The hypothalamus in Parkinson's disease. Ann Neurol 1978;3:129-133.
11. Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease; a clinicopathological study. J Neurol Neurosurg Psychiatry 1992;55:181-184.
12. Consensus statement: definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996;6:125-126.
13. Fearnley J, Lees A. Striatonigral degeneration. A clinicopathological study. Brain 1990;113:1823-1842.
14. Spokes E, Bannister R, Oppenheimer D. Multiple system atrophy with autonomic failure. Clinical histological and neurochemical observations in four cases. J Neurol Sci 1979;43:59-82.
15. Tsai A, Maehara K, Iizuka R. Loss of catecholaminergic neurone in the hypothalamus of multiple system atrophy. Rinsho Shinkeigaku 1992;32:125-130.
16. Konagaya Y, Konagaya M, Takayanagi T. Tuberoinfundibular dopaminergic system and anterior pituitary dopamine receptor in Shy-Drager syndrome. J Neural Sci 1985;67:93-103.
17. Kimber J, Watson L, Mathias CJ. Distinction of multiple system atrophy from idiopathic Parkinson's disease by stimulation of GH release with clonidine. Lancet 1997;349:1877-1881.
18. Mathias CJ, Williams A. The Shy Drager Syndrome (and MSA). In: Calne D, ed. Neurodegenerative Diseases, 1st ed. Philadelphia, PA: WB Saunders, 1994:743-767.
19. Mathias CJ, Bannister R. Investigation of autonomic disorders. In: Mathias CJ, Bannister R, eds. Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nenous System, 4th ed. Oxford: Oxford University Press, 1999:169-195.
20. Mathias CJ. Autonomic disorders and their recognition. N Engl J Med 1997;10:721-724.
21. Frohman LA, Downs TR. Measurement of GHRF. Methods Enzymol 1986;124:371-389.
22. May C, Ham I, Heslop K, Stone F, Mathias CJ. Intravenous morphine causes hypotension, hypoglycaemia and increases sympathoadrenal activity in the conscious rat. Clin Sci 1988;75:71-77.
23. Everitt B, Meister B, Hokfelt T, et al. Immunohistochemistry of transmitters, peptides and DARPP-32 in the hypothalamic arcuate-median eminence complex with special reference to coexistence with dopamine neurones. Brain Res 1986;396:97-155.
24. Bansal S, Lee A, Woolf P. Dopaminergic stimulation and inhibition of growth hormone secretion in normal man: studies of the pharmacological specificity. J Clin Endocrinol Metab 1981;53: 1273-1277.
25. Muller EE. Neural control of somatotrophe function. Physiological Reviews 1987;67:962-1053.
26. Saito H, Saito S, Yamasaki R, Hosoi E. Clinical value of radioimmunoassay plasma growth hormone releasing factor. Lancet 1984;ii:401-402.
27. Chihara K, Kashio Y, Kita T, et al. L-Dopa stimulates release of hypothalamic growth hormone releasing hormone in humans. J Clin Endocrinol Metab 1986;62:466-473.
28. Taipanainen P, Knip M, Lautula P, Leppalauto J. Variable plasma GHRH and GH responses to clonidine, L-dopa and insulin in normal man. J Clin Endocrinol Metab 1988;67:845-849.
29. Saito H, Hosoi E, Yamasaki R, et al. Immunoreactive GHRH in the feto-placental circulation and differential effects of L-dopa, L-arginine and somatostatin-14 on plasma levels of IR-GHRH in normal adults. Horm Metab Res 1997;29:184-189.
30. Page M, Dieguez C, Valcalvi R, Koppeschar H, Scanlon M. Growth hormone releasing hormone 1-44 NH2 and 1-40 OH levels in normal subjects during growth hormone stimulation tests. Clin Endocrinol (Oxf) 1994;40:97-102.
31. Donnadieu M, Evain-Brion D, Tonon M, Vaudry H, Job J. Variations of plasma GHRH levels during GH stimulation tests in children. J Clin Endocrinol Metab 1985;60:1132-1134.
32. Tallo D, Malarkey W. Adrenergic and dopaminergic modulation of growth hormone and prolactin secretion in normal and tumour bearing human pituitaries in monolayer culture. J Clin Endocrinol Metab 1981;53:1278-1284.
33. Williams T, Lightman S, Johnson M, Carmichael D, Bannister R. Selective deficit in gonadotrophin secretion in patients with autonomic failure. Clin Endocrinol (Oxf) 1989;30:285-292.
34. Thomaides T, Ray-Chaudhuri K, Maule S, Watson L, Marsden CD, Mathias CJ. Growth hormone response in central and peripheral primary autonomic failure. Lancet 1992;340:263-266.
35. Polinsky R, Kopin I, Ebert M, Recant L. Hormonal response to hypoglycaemia in patients with orthostatic hypotension. Life Sci 1981;29:417-425.
36. Vogel H, Ketsche R. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease. J Neurol 1986;233:149-152.
37. Mars H, Geneuth S. Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition. Clin Pharmacol Ther 1973;14:390-395.
38. Gibb W, Lees AJ, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
39. Kremer H, Bots G. Lewy bodies in the lateral hypothalamus: do they imply neuronal loss? Mov Disord 1993;8:315-320.
40. Matzuk M, Saper C. Preservation of hypothalamic dopaminergic neurones in Parkinson's disease. Ann Neurol 1985;18:552-555.
41. Hornykiewitz O. Biochemical abnormalities in some extra-striatal neuronal systems in Parkinson's disease. In: Rinne U, Klinger M, Stamm G, eds. Parkinson's Disease: Current Progress, Problems and Management. Proceedings of the North European symposium on Parkinson's disease. Amsterdam: Elsevier, 1980:109-119.
42. Lloyd K, Hornykiewitz O. Parkinson's disease: activity of dopadecarboxylase in discrete brain regions. Science 1970;170:1212-1213.
43. Rinne UK. Neurendocrine and extrapyramidal dopamine neurones in Parkinson's disease. In: Miller EE, Agnoli A, eds. Neuroendocrine Correlates in Neurology and Psychiatry. Amsterdam: Elsevier, 1979:119-125.
44. Javoy-Agid F, Ruberg M, Pique L, et al. Biochemistry of the hypothalamus in Parkinson's disease. Neurology 1984;34:672-675.
45. MacLeod R, Lehmeyer J. Studies on the mechanism of the dopamine mediated inhibition of prolactin secretion. Endocrinology 1974;94:1077-1085.
46. De Camilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin secreting adenomas. Nature 1979;278: 252-254.
47. Hentschel K, Cheung S, Moore K, Lookingland K. Pharmacological evidence that neurotensin mediates prolactin induced activation of TIDA neurones. Neuroendocrinology 1998;68:71-76.
48. Demarest K, Riegle G, Moore K. Prolactin-induced activation of tuberoinfundibular neurones: evidence for both a rapid 'tonic' and a delayed 'induction' component. Neuroendocrinology 1984;38: 467-475.
49. Gudelsky G, Moore K. Differential drug effects on dopamine concentrations and rates of turnover in the median eminence, oflactory tubercle and corpus striatum. J Neural Transm 1976;38:95-105.
50. Demarest K, Moore K. Comparison of dopamine synthesis regulation in terminals of mesolimbic, nigrostriatal, tuberoinfundibular and tuberohypophyseal neurones. J Neural Transm 1979;46:263-277.
51. Llau M, Durrieu G, Tran M, Senard J, Rascol O, Montastruc J. A study of dopaminergic sensitivity in Parkinson's disease: comparison in 'de-novo' and L-DOPA TREATED PATIENTS. CLIN NEUROPHARMACOL 1996;19:420-427.
52. Kansal P, Buse J, Talbot O, Buse M. The effect of L-dopa on plasma growth hormone, insulin and thyroxine. J Clin Endocrinol Metab 1972;34:99-105.
53. Siritori C, Bolme P, Aznaroff D. Metabolic responses to acute and chronic L-dopa administration in patients with Parkinson's disease. N Engl J Med 1972;287:729-733.
54. Lundberg P. Blood levels of FSH, LH, TSH and GH in parkinsonian patients before and during levodopa therapy. Acta Neurol Scand 1972;48:427-432.
55. Brown W, Van Woert M, Ambani L, Effect of apomorphine on GH release in humans. J Clin Endocrinol Metab 1973;37:463-465.
56. Boyd A, Lebovitz H, Feldman J. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration with L-dopa. J Clin Endocrinol Metab 1971;33:829-837.
57. Lebovitz H, Skyler J, Boyd A. L-Dopa and growth hormone secretion in man. In: McDowell F, Barbeau A, eds. Advances in Neurology, vol 5. New York, NY: Raven Press, 1974:461-469.
58. Laihinen A, Rinne U. Dopamine receptor function in Parkinson's disease - in vivo studies with prolactin responses. In: Yahr M, Bergmann K. eds. Advances in Neurology. New York, NY: Raven Press, 1986:249-252.
59. Falaschi P, Ruggieri S, Rocco A, et al. Confronto tra la riposta della PRL e dell'ormone della cresita a farmaci dopaminergic in pazientzi parkinsoni. In: Agnoli A, Bertolani G, Guanella A, eds. Atti della VII Riunione della Lega Italiana Contro il Morbido di Parkinson. Rome, 1981:117-126.
60. Lawton N, MacDermot J. Abnormal regulation of prolactin release in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1980;43:1012-1015.
61. Kant J, Baumann R, Anderson S, Mougey E. Effects of controllable vs uncontrollable chronic stress on stress responsive plasma hormones. Physiology and Behaviour 1992;51:1285-1288.
62. Guyda H, Friesen H. Serum prolactin levels in humans from birth to adult life. Pediatr Res 1973;7:534-540.
63. Racagni G, Apud J, Cocchi D, Locatelli V, Muller EE. GABAergic control of anterior pituitary secretion. Life Sci 1982;31:823-828.